Search: onr:"swepub:oai:gup.ub.gu.se/168814" >
Treatment of Alzhei...
Treatment of Alzheimer's disease with clioquinol.
-
- Regland, Björn, 1947 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för klinisk neurovetenskap,Institute of Clinical Neurosciences
-
Lehmann, W (author)
-
Abedini, I (author)
-
show more...
-
- Blennow, Kaj, 1958 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för klinisk neurovetenskap,Institute of Clinical Neurosciences
-
- Jonsson, Michael, 1955 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för klinisk neurovetenskap,Institute of Clinical Neurosciences
-
- Karlsson, Ingvar, 1941 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för klinisk neurovetenskap,Institute of Clinical Neurosciences
-
- Sjögren, Magnus (author)
- Gothenburg University,Göteborgs universitet,Institutionen för klinisk neurovetenskap,Institute of Clinical Neurosciences
-
- Wallin, Anders, 1950 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för klinisk neurovetenskap,Institute of Clinical Neurosciences
-
Xilinas, M (author)
-
- Gottfries, Carl-Gerhard, 1928 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för klinisk neurovetenskap,Institute of Clinical Neurosciences
-
show less...
-
(creator_code:org_t)
- 2001
- 2001
- English.
-
In: Dementia and geriatric cognitive disorders. - 1420-8008. ; 12:6, s. 408-14
- Related links:
-
https://gup.ub.gu.se...
Abstract
Subject headings
Close
- As heavy metal ions may be implicated in the formation of senile plaques in Alzheimer-afflicted brains, treatment with clioquinol was tested in 20 patients with Alzheimer's disease. Clioquinol is a chelator that crosses the blood-brain barrier and has greater affinity for zinc and copper ions than for calcium and magnesium ions. Treatment was given for 21 days at doses of 20 mg/day to 10 patients and 80 mg/day to another 10 patients. The study was blind to the dosages but included no controls. Cerebrospinal fluid (CSF) investigations revealed a significant increase at day 7 and a decrease at day 21 in Tau protein and growth-associated protein (GAP43). These proteins are increased in Alzheimer's disease and considered as rather stable markers. The initial increase may indicate a temporary cytotoxicity to the brain and/or an increased release into the CSF from stores in the tissue, possibly from senile plaques where the proteins are accumulated. The levels of CSF-Tau protein correlated positively and significantly with the serum levels of copper and also with the serum copper/zinc ratio. Clinical ratings showed slight improvement after 3 weeks treatment with clioquinol in this open study.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Neurosciences (hsv//eng)
Keyword
- Aged
- Aged
- 80 and over
- Alzheimer Disease
- blood
- cerebrospinal fluid
- drug therapy
- Chelating Agents
- administration & dosage
- adverse effects
- therapeutic use
- Chelation Therapy
- methods
- Clioquinol
- administration & dosage
- adverse effects
- therapeutic use
- Copper
- blood
- Dose-Response Relationship
- Drug
- Female
- GAP-43 Protein
- cerebrospinal fluid
- drug effects
- Humans
- Male
- Middle Aged
- Treatment Outcome
- Zinc
- blood
- tau Proteins
- cerebrospinal fluid
- drug effects
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Regland, Björn, ...
-
Lehmann, W
-
Abedini, I
-
Blennow, Kaj, 19 ...
-
Jonsson, Michael ...
-
Karlsson, Ingvar ...
-
show more...
-
Sjögren, Magnus
-
Wallin, Anders, ...
-
Xilinas, M
-
Gottfries, Carl- ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Basic Medicine
-
and Neurosciences
- Articles in the publication
-
Dementia and ger ...
- By the university
-
University of Gothenburg